Apimeds Pharmaceuticals US, Inc. (APUS) stock
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
$2.27−0.09 (-3.81%)
Close on Nov 12, 2026Market cap $3.43MP/E –Yield –
Apimeds Pharmaceuticals US ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Apimeds Pharmaceuticals US
Apimeds Pharmaceuticals US has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?